gout gout, hyperuricemia, uric acid, allopurinol
Conditions
Interventions
The active arm receives allopurinol 50 mg/day (D1-7) and gradually increase to 100 mg/day and 200 mg/day on day 8-14, and 15-28 respectively. ,The placebo arm receives placeob (identical tablet to act
Active Comparator Drug,Placebo Comparator Drug
allopurinol,placebo
Sponsors
Faculty of Medicine Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 20 to 70 years 2. Crystal proven gout or meet American College of Rheumatology/European League Against Rheumatism 2015 classification criteria for gout 3. Onset of attack within 72 hours with at pain score determined by visual analog scale (VAS) of 4 or more 4. Meet at least 1 criterion for uric lowering therapy, which include: - Gout with subcutaneous tophi(s) - Evidence of radiologic damage by any radiologic modalities - Patients with frequent flare (2 times or more/year) - Patients experiencing first flare with chronic kidney disease stage 3 or more, serum uric acid > 9 mg/dL or urolithiasis
Exclusion criteria
Exclusion criteria: 1. eGFR <30 ml/min/1.73 sq. m. 2. Currently using urate lowering therapy (allopurinol, febuxostat, probenecid, benzbromarone, and sulfinpyrazone) or history of using it within the past 30 days.having uric lowering therapy treatment or history of using one in the past 30 days. 3. History of allopurinol hypersensitivity syndrome 4. Received drugs for acute treatment (NSAIDs, colchicine, or corticosteroids) for > 48 hours period 5. Uncontrolled infection/severe sepsis or have any disease that the investigators consider that the patient might not be suitable for the study 6. Poor controlled diabetes mellitus (HbA1c equal to or more than 8%) 7. Active cancer 8. Unable to communicate or perform visual analog scale/patient global assessment 9. Unable to take oral medication 10. Elevation of liver enzymes (AST/ALT) more thatn to times normal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of arthritis the days that the patient has pain less than 2 in 10 visual analog scale Pain by visual analog scale | — |
Secondary
| Measure | Time frame |
|---|---|
| patient global assessment D1, D8, D15, D28 Visual analog scale,health related quality of life D1, D8, D15, D 28 HAQ score,Inflammatory marker D1, D8, D15, D28 ESR, CRP,side effect any time from D1-D28 symptoms of side effects | — |
Countries
Thailand
Contacts
Public ContactWorawit Louthrenoo
Faculty of Medicine, Chiang Mai University
Outcome results
None listed